2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1610

Incremental Benefits to Quality of Life Associated with Achieving Higher Levels of American College of Rheumatology Response and Skin Clearance in Patients with Psoriatic Arthritis
Abstract Number: 1227

Indicator Opportunistic Infections after Biological Treatment in Rheumatoid Arthritis, 10 Years Follow up in Clinical Practice
Abstract Number: 1208

Indicators for Active Musculoskeletal Ultrasound Findings of Psoriatic Arthritis Vary on Each Body Part
Abstract Number: 14

Individual RA-Derived Monoclonal Anti-Citrullinated Protein Autoantibodies (ACPA) Have Extensive Citrulline Multi-Reactivity Demonstrated By a Large-Scale Protein Array Platform
Abstract Number: 1919

Individual Short-Acting Opioids and the Risk of Opioid-Related Adverse Events in Adolescents
Abstract Number: 602

Individualised Infliximab Treatment: A Treatment Strategy Based on Therapeutic Drug Monitoring
Abstract Number: 1893

Indoleamine-2,3-Dioxygenase in Murine and Human Systemic Lupus Erythematosus
Abstract Number: 2078

Induction of Netosis in Ankylosing Spondylitis: Association to Disease Pathogenesis and Modulation By Anti-Tnfα Therapy
Abstract Number: 1516

Infection Events in Japanese Patients with Rheumatoid Arthritis Treated with Tofacitinib: Interim All-Case Post-Marketing Surveillance
Abstract Number: 1883

Infections Are Associated With Increased Risk of Giant Cell Arteritis – a Population-Based Case-Control Study From Southern Sweden
Abstract Number: 366

Infectious Complications of Immunosuppressive Therapy in Patients with Common Variable Immunodeficiency (CVID) and Inflammatory Arthritis
Abstract Number: 2071

Inflammation at Distant Immunocompetent Sites Combined with a Protocol of Forced Exercise Induces Mild Joint Inflammation
Abstract Number: 933

Inflammation in the Hippocampus Affects Insulin-like Growth Factor-1 Receptor Signaling and Contributes to Neurological Sequelae in Rheumatoid Arthritis
Abstract Number: 666

Inflammation on MRI of the Sacroiliac Joints Is Highly Associated with Structural Damage in Axial Spondyloarthritis Patients in Clinical Practice: Data from the ASAS and DESIR Cohorts
Abstract Number: 1398

Inflammatory Arthritis DMARD Adverse Effects Are Pervasive and Can Greatly Impact Quality of Life and Work and Social Roles: Initial Results from the Omeract Safety Working Group

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].